CRISPR Therapeutics AG (NASDAQ:CRSP) shares, rose in value on Wednesday, January 22, with the stock price up by 6.48% to the previous day’s close as strong demand from buyers drove the stock to $44.20.
Actively observing the price movement in the last trading, the stock closed the session at $41.51, falling within a range of $41.1901 and $45.77. The value of beta (5-year monthly) was 1.662. Referring to stock’s 52-week performance, its high was $91.10, and the low was $36.52. On the whole, CRSP has fluctuated by 7.65% over the past month.
With the market capitalization of CRISPR Therapeutics AG currently standing at about $3.77 billion, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 7.43M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRSP’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CRSP currently trading nearly 8.89% and -2.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 56.86, while the 7-day volatility ratio is showing 5.23% which for the 30-day chart, stands at 4.58%. Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 1.67, and its average true range (ATR) is 2.26.
A comparison of CRISPR Therapeutics AG (CRSP) with its peers suggests the former has fared considerably weaker in the market. CRSP showed an intraday change of 6.48% in last session, and over the past year, it shrunk by -28.70%%.
Data on historical trading for CRISPR Therapeutics AG (NASDAQ:CRSP) indicates that the trading volumes over the past 10 days have averaged 1.82 and over the past 3 months, they’ve averaged 1.81 million. According to company’s latest data on outstanding shares, there are 85.34 million shares outstanding.
Nearly 4.30% of CRISPR Therapeutics AG’s shares belong to company insiders and institutional investors own 69.43% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 19.1 million shares as on 2024-12-31, resulting in a short ratio of 9.89. According to the data, the short interest in CRISPR Therapeutics AG (CRSP) stood at 2536.00 of shares outstanding as of 2024-12-31; the number of short shares registered in 2024-11-29 reached 18.15 million. The stock has risen by 12.30% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRSP stock heading into the next quarter.
